Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y₁₂ and Link to Residual Platelet Reactivity

Area of Science:

• Hematology and Thrombosis Research
• Platelet Physiology and Function
• Cardiovascular Disease Pathogenesis

Background:

• Adenosine diphosphate (ADP)-induced platelet activation results in cell surface expression of tissue factor (TF).
• The specific roles of ADP receptors, P2Y₁ and P2Y₁₂, in modulating platelet TF exposure remain largely uncharacterized.
• Understanding these pathways is critical for managing thrombotic risk in cardiovascular diseases.

Purpose of the Study:

• To investigate the involvement of P2Y₁ and P2Y₁₂ receptors in ADP-induced TF exposure on platelets.
• To evaluate the modulation of TF-positive (TF^pos) platelets in patients with coronary artery disease undergoing anti-P2Y₁₂ therapy.
• To elucidate the intracellular localization of TF within platelets.

Main Methods:

• In vitro analysis of P2Y₁ or P2Y₁₂ antagonist effects on ADP-induced TF expression and activity using flow cytometry and thrombin generation assays.
• Ex vivo assessment of P2Y₁₂ inhibition on TF expression in coronary artery disease patients (n=238) treated with clopidogrel, prasugrel, or ticagrelor, measured by VASP platelet reactivity index.
• Transmission electron microscopy (TEM) and analysis of gray platelet syndrome patients to determine TF intracellular localization and release mechanisms.

Main Results:

• P2Y₁₂ inhibition significantly reduced ADP-induced TF^pos-platelets in vitro in a concentration-dependent manner, while P2Y₁ inhibition had no significant effect.
• In coronary artery disease patients, P2Y₁₂ inhibition correlated with reduced ADP-induced platelet TF expression, although a subset of clopidogrel responders showed residual TF exposure.
• A VASP platelet reactivity index below 20% effectively identified patients with low TF^pos-platelets, and colchicine impaired TF expression but not α-granule release, suggesting TF is stored in the open canalicular system.

Conclusions:

• Platelet TF expression is predominantly regulated by the P2Y₁₂ receptor, with P2Y₁₂ antagonists demonstrating efficacy in downregulating TF^pos-platelets.
• Assessing TF^pos-platelets in patients treated with clopidogrel can identify individuals with residual platelet reactivity, even among apparent good responders.
• TF is stored within the platelet's open canalicular system, and its membrane exposure upon activation is a distinct process from α-granule release.